Literature DB >> 17279093

Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients.

A W Henkel1, P S Dittrich, T W Groemer, E A Lemke, J Klingauf, H W Klafki, P Lewczuk, H Esselmann, P Schwille, J Kornhuber, J Wiltfang.   

Abstract

The diagnostic potential of large A beta-peptide binding particles (LAPs) in the cerebrospinal fluid (CSF) of Alzheimer's dementia (AD) patients and non-AD controls (nAD) was evaluated. LAPs were detected by confocal spectroscopy in both groups with high inter-individual variation in number. Molecular imaging by confocal microscopy revealed that LAPs are heterogeneous superaggregates that could be subdivided morphologically into four main types (LAP 1-4). LAP-4 type, resembling a 'large chain of pearls', was detected in 42.1% of all nAD controls but it was virtually absent in AD patients. LAP-4 type could be selectively removed by protein A beads, a clear indication that it contained immunoglobulins in addition to beta-amyloid peptides (A beta 1-42). We observed a close correlation between LAPs and immunoglobulin G (IgG) concentration in CSF in controls but not in AD patients. Double labeling of LAPs with anti-A beta and anti-IgG antibodies confirmed that LAP-4 type consisted of A beta and IgG aggregates. Our results assign a central role to the immune system in regulating A beta1-42 homeostasis by clustering this peptide in immunocomplexes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17279093     DOI: 10.1038/sj.mp.4001947

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  10 in total

Review 1.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

2.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

3.  Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study.

Authors:  Andreas Wolfram Henkel; Katharina Müller; Piotr Lewczuk; Thorsten Müller; Katrin Marcus; Johannes Kornhuber; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-03-14       Impact factor: 3.575

Review 4.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

5.  Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

Authors:  M Britschgi; C E Olin; H T Johns; Y Takeda-Uchimura; M C LeMieux; K Rufibach; J Rajadas; H Zhang; B Tomooka; W H Robinson; C M Clark; A M Fagan; D R Galasko; D M Holtzman; M Jutel; J A Kaye; C A Lemere; J Leszek; G Li; E R Peskind; J F Quinn; J A Yesavage; J A Ghiso; T Wyss-Coray
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

6.  Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS.

Authors:  Chuanhai Cao; Gary W Arendash; Alexander Dickson; Malgorzata B Mamcarz; Xiaoyang Lin; Douglas W Ethell
Journal:  Neurobiol Dis       Date:  2009-01-08       Impact factor: 5.996

7.  Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Authors:  Johanna Magga; Lakshman Puli; Rea Pihlaja; Katja Kanninen; Suvi Neulamaa; Tarja Malm; Wolfgang Härtig; Jens Grosche; Gundars Goldsteins; Heikki Tanila; Jari Koistinaho; Milla Koistinaho
Journal:  J Neuroinflammation       Date:  2010-12-07       Impact factor: 8.322

8.  Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.

Authors:  Susanne Aileen Funke
Journal:  Int J Alzheimers Dis       Date:  2011-11-02

Review 9.  Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?

Authors:  Kurt A Jellinger; Bernd Janetzky; Johannes Attems; Elisabeth Kienzl
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

Review 10.  Potential sources of interference on Abeta immunoassays in biological samples.

Authors:  Hugo Vanderstichele; Erik Stoops; Eugeen Vanmechelen; Andreas Jeromin
Journal:  Alzheimers Res Ther       Date:  2012-10-17       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.